| scholarly article | Q13442814 |
| P818 | arXiv ID | 2004.07086 |
| P356 | DOI | 10.1016/J.IJBIOMAC.2020.09.098 |
| P932 | PMC publication ID | 7495146 |
| P698 | PubMed publication ID | 32950529 |
| P2093 | author name string | Mahmudul Hasan | |
| Mohammad Jakir Hosen | |||
| Md Nazmul Hasan | |||
| Tohura Tahsin | |||
| Md Sorwer Alam Parvez | |||
| Ziaul Karim | |||
| Jomana Jaman | |||
| Md Adnan Karim | |||
| P2860 | cites work | Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro | Q84360011 |
| A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster | Q86737473 | ||
| Coronavirus puts drug repurposing on the fast track | Q86846316 | ||
| Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study | Q87191917 | ||
| Sensitivity of Chest CT for COVID-19: Comparison to RT-PCR | Q87281376 | ||
| SARS-CoV-2 and COVID-19: The most important research questions | Q87945075 | ||
| Discovering drugs to treat coronavirus disease 2019 (COVID-19) | Q87963364 | ||
| Therapeutic options for the 2019 novel coronavirus (2019-nCoV) | Q88045822 | ||
| What we know so far: COVID-19 current clinical knowledge and research | Q90088931 | ||
| Similarity in Case Fatality Rates (CFR) of COVID-19/SARS-COV-2 in Italy and China | Q90133538 | ||
| The potential chemical structure of anti-SARS-CoV-2 RNA-dependent RNA polymerase | Q90292823 | ||
| COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression | Q90496530 | ||
| Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study | Q90720676 | ||
| Benchmarking of different molecular docking methods for protein-peptide docking | Q91337450 | ||
| The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro | Q91598701 | ||
| LARMD: integration of bioinformatic resources to profile ligand-driven protein dynamics with a case on the activation of estrogen receptor | Q91678523 | ||
| Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): An Update | Q93240889 | ||
| Structural basis of potential binding mechanism of remdesivir to SARS-CoV-2 RNA dependent RNA polymerase | Q96293346 | ||
| PatchDock and SymmDock: servers for rigid and symmetric docking | Q24813335 | ||
| ZINC--a free database of commercially available compounds for virtual screening | Q27656255 | ||
| AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading | Q27860652 | ||
| The Amber biomolecular simulation programs | Q27860745 | ||
| Purification of Zika virus RNA-dependent RNA polymerase and its use to identify small-molecule Zika inhibitors | Q28223065 | ||
| The design of drugs for HIV and HCV | Q28259321 | ||
| A BOILED-Egg To Predict Gastrointestinal Absorption and Brain Penetration of Small Molecules | Q28822513 | ||
| LigPlot+: multiple ligand-protein interaction diagrams for drug discovery | Q29615875 | ||
| The RCSB protein data bank: integrative view of protein, gene and 3D structural information | Q31139806 | ||
| Informatics and modeling challenges in fragment-based drug discovery. | Q33287007 | ||
| iGEMDOCK: a graphical environment of enhancing GEMDOCK using pharmacological interactions and post-screening analysis | Q33826989 | ||
| Favipiravir (T-705), a novel viral RNA polymerase inhibitor | Q34374652 | ||
| Coronaviruses - drug discovery and therapeutic options. | Q34513643 | ||
| PLIP: fully automated protein-ligand interaction profiler | Q35601315 | ||
| Orthopoxvirus targets for the development of antiviral therapies | Q36074391 | ||
| ZINCPharmer: pharmacophore search of the ZINC database | Q36088378 | ||
| PharmaGist: a webserver for ligand-based pharmacophore detection | Q36749332 | ||
| In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling | Q36840592 | ||
| Deterministic pharmacophore detection via multiple flexible alignment of drug-like molecules | Q37234706 | ||
| Antiviral chemotherapy for infection with human immunodeficiency virus | Q38745078 | ||
| Molecular dynamics analysis to evaluate docking pose prediction | Q41227055 | ||
| SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules | Q42318665 | ||
| Estimation of ADME properties with substructure pattern recognition. | Q43821108 | ||
| In Silico Estimation of Chemical Carcinogenicity with Binary and Ternary Classification Methods. | Q45954699 | ||
| In silico prediction of chemical Ames mutagenicity. | Q45960116 | ||
| DrugBank 5.0: a major update to the DrugBank database for 2018. | Q47128239 | ||
| Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. | Q53704198 | ||
| Database resources of the National Center for Biotechnology Information | Q57444434 | ||
| Drug Repurposing for Viral Infectious Diseases: How Far Are We? | Q59360930 | ||
| Drug Repurposing Approaches for the Treatment of Influenza Viral Infection: Reviving Old Drugs to Fight Against a Long-Lived Enemy | Q63246314 | ||
| P921 | main subject | SARS-CoV-2 | Q82069695 |
| P577 | publication date | 2020-09-17 | |
| P1433 | published in | International Journal of Biological Macromolecules | Q6051322 |
| P1476 | title | Prediction of potential inhibitors for RNA-dependent RNA polymerase of SARS-CoV-2 using comprehensive drug repurposing and molecular docking approach |
| Q108084285 | RNA-dependent RNA polymerase (RdRp) inhibitors: The current landscape and repurposing for the COVID-19 pandemic | cites work | P2860 |
Search more.